Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02288273 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.
A Phase 4 study of Type 2 Diabetes, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 239
- Enrollment target
- 20
- Study locations
NCT02288273: Completed Phase 4 study of Type 2 Diabetes, sponsored by AstraZeneca.
NCT02288273 is a Phase 4 study of Type 2 Diabetes that has completed, run by AstraZeneca. The registered enrollment target is 239 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02288273, a Phase 4 study of Type 2 Diabetes, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 239 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in Metformin-treated Patients with Type 2 Diabetes.
Primary Outcome
Change in 24-hour mean weighted glucose from baseline (Day -1/1) to Day 6 of Week 4 (Day 27/28) and to Day 6 of Week 10 (Day 69/70).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Bydureon
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Chino
- Research Site - Los Angeles
- Research Site - North Hollywood
- Research Site - Santa Ana
- Research Site - Spring Valley
- Research Site - Tustin
- Research Site - Walnut Creek
Florida
- Research Site - Hollywood
- Research Site - Miami
- Research Site - Port Orange
Ohio
- Research Site - Franklin
- Research Site - Marion
Georgia
- Research Site - Marietta
Illinois
- Research Site - Chicago
Minnesota
- Research Site - Edina
Missouri
- Research Site - St Louis
Montana
- Research Site - Butte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
What the finished NCT02288273 record still lists
NCT02288273 is an interventional study that assigns participants to a tested intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02288273 names 20 study sites across 10 states, led by California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT02288273 about?
NCT02288273 is a clinical study titled "Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.". A Randomized, Double-blind, Parallel-group Study to Evaluate the Effect of Bydureon Compared with Placebo on 24-hour Glucose Control in Metformin-treated Patients with Type 2 Diabetes.
What is the current status of trial NCT02288273?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 239 participants. The study started on 2014-12. Estimated completion is 2015-08.
What conditions does trial NCT02288273 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT02288273?
The interventions under investigation include: Placebo (DRUG), Bydureon (DRUG).
Who is sponsoring clinical trial NCT02288273?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02288273 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02288273's enrollment target sits among peer trials
239 85th of 327 higher than 243 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
RECRUITING · Phase 4
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
RECRUITING · Phase 4
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
RECRUITING · Phase 4
-
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia